Alnylam (ALNY) Q1 2023: TTR Franchise Surges 75% in U.S., CNS RNAi Data Opens New Pipeline Horizons

May 4, 2023 | By EarningsIQ Research

Alnylam’s U.S. TTR franchise accelerated with 75% growth, fueled by Amvuttra’s expanding adoption and robust patient metrics. The company’s CNS RNAi program delivered first-in-human proof of concept, marking a pivotal platform milestone. Management maintained full-year guidance, emphasizing sustainable innovation and commercial execution as key levers for long-term value creation.

Summary

• Amvuttra Drives Franchise Expansion: Patient growth, prescriber base, and compliance metrics all point to durable TTR momentum.
• CNS Platform Breakthrough: Human proof-of-concept for RNAi in the brain unlocks new therapeutic avenues and pipeline leverage.
• Guidance Reaffirmed: Management signals confidence in commercial ramp and pipeline execution for 2023 and beyond.

Business Overview

Alnylam is a biotechnology company pioneering RNA interference (RNAi), a therapeutic modality that silences disease-causing genes. The company’s commercial portfolio includes four approved products targeting rare genetic diseases, with the TTR franchise (Onpattro and Amvuttra, both for transthyretin amyloidosis) as its largest revenue driver. Alnylam’s business model combines direct product sales, strategic collaborations (notably with Regeneron), and royalties, while investing heavily in a broad clinical pipeline spanning rare and more prevalent diseases.

Performance Analysis

Alnylam’s Q1 delivered broad-based revenue growth, driven by the rapid uptake of Amvuttra in the U.S. and steady international expansion. The TTR franchise contributed the majority of product revenue, with U.S. sales up 75% year-over-year and global TTR sales rising 49% despite a five-point FX headwind. New patient starts, high switch rates from Onpattro, and expanding prescriber adoption all underpinned this outperformance. Internationally, Japan’s Amvuttra launch drove double-digit sequential growth, offset by temporary inventory destocking.

The ultra-rare portfolio (Givlaari and Oxlumo) delivered 45% year-over-year growth, though sequential gains were modest due to seasonal payer dynamics and inventory timing. Collaboration and royalty revenues grew 41%, reflecting increased Regeneron activity and Novartis’ Leqvio sales. Gross margin compressed by two points, primarily from higher Amvuttra royalties to Sanofi, partially offset by lower manufacturing costs. R&D and SG&A expense growth tracked pipeline and launch investments, but operating loss narrowed as top-line strength outpaced cost escalation.

• TTR Franchise Momentum: U.S. TTR sales achieved three consecutive quarters of 70%+ growth, reflecting Amvuttra’s successful launch and patient conversion dynamics.
• Pipeline Investment: R&D spend rose 35% as Alnylam advanced multiple late-stage and early-stage programs, including CNS and hypertension assets.
• Cash Position: $2.1 billion in liquidity provides ample runway for pipeline and commercial execution, with management reiterating path to financial self-sustainability.

Overall, the quarter showcased strong operational leverage from the TTR franchise and early validation of Alnylam’s CNS RNAi ambitions.

Executive Commentary

Strategic Positioning

1. TTR Franchise Expansion

Amvuttra, next-gen TTR silencer, has fundamentally shifted the growth curve for Alnylam’s core franchise. With robust new patient adds, high compliance, and a growing prescriber base, management sees continued category expansion—not just patient switching. U.S. and Japan launches are outpacing expectations, and international markets are primed for further Amvuttra uptake.

2. CNS Platform Validation

The interim Phase I data for ALN-APP, targeting amyloid precursor protein in Alzheimer’s and CAA, provides first-ever human proof for CNS-directed RNAi. Durable, dose-dependent knockdown (up to 90%) with infrequent dosing potential (quarterly or less) supports a modular CNS pipeline. Regulatory dialogue will determine U.S. multi-dose study timing, but platform expansion beyond rare disease is now credible.

3. Pipeline Breadth and Acceleration

Alnylam’s pipeline spans late-stage (Apollo B, Helios B, TTR-SC04) and mid-stage programs (Zalbiceran for hypertension, ALN-KHK for diabetes), with multiple value-creating milestones ahead. The company is leveraging platform learnings to accelerate new candidates—potentially using innovative trial designs and historical controls to compress development timelines, especially for next-gen TTR assets.

4. Commercial Model and Access Strategy

Alnylam’s approach to payer access and patient support—especially for Medicare/Medicaid patients—remains a core competitive advantage. Value-based agreements ensure high compliance and low out-of-pocket costs for most patients, supporting both uptake and retention as new therapies launch and the competitive landscape evolves.

5. Capital Discipline and Sustainability

Despite elevated R&D and SG&A investment, management is targeting self-sustainability, balancing pipeline acceleration with prudent cash management. Guidance was reiterated, reflecting confidence in both the commercial ramp and pipeline execution.

Key Considerations

Alnylam’s Q1 results reinforce its transition from a rare disease pure-play to a platform-driven innovator with commercial scale. The following considerations will shape investor focus in coming quarters:

• Amvuttra Launch Dynamics: Sustained high switch rates and new patient adds indicate durable growth, but monitoring for potential bolus effects and payer-driven seasonality is warranted.
• CNS RNAi Risk/Reward: Regulatory engagement and safety profile in multi-dose CNS studies will determine how quickly Alnylam can scale its new platform beyond proof of concept.
• Pipeline Catalysts: Multiple late-stage readouts (Apollo B 18-month data, Helios B, TTR-SC04, Zalbiceran) could drive step-changes in addressable market and valuation.
• Competitive Landscape: New TTR silencers and evolving standards of care may intensify market share battles; Alnylam’s experience and product profile differentiation are key moats.
• FX and Royalty Headwinds: Currency swings and royalty obligations (notably to Sanofi) will continue to influence reported margins and cash flows.

Risks

Key risks include regulatory uncertainty for CNS assets (notably the FDA partial hold on ALN-APP multi-dose studies), competitive pressure from emerging TTR silencers, and potential for payer or reimbursement headwinds as the rare disease market matures. FX volatility and royalty drag may also impact reported results. Investors should monitor the pace of pipeline advancement, especially in CNS and hypertension, for signs of either acceleration or delay.

Forward Outlook

For Q2 and the remainder of 2023, Alnylam guided to:

• Combined net product revenues of $1.2 to $1.285 billion for the full year.
• Collaboration and royalty revenues of $100 to $175 million.
• Combined non-GAAP R&D and SG&A expenses of $1.575 to $1.65 billion.

Management highlighted upcoming catalysts, including Apollo B 18-month data, Helios B dosing results, and top-line Zalbiceran Phase II data. Execution on global launches and pipeline milestones are expected to drive both near-term and long-term growth.

• Commercial growth in TTR and ultra-rare franchises remains a top priority.
• Regulatory progress and data readouts from late-stage studies will be closely watched.

Takeaways

Alnylam’s Q1 demonstrated the commercial and scientific leverage of its RNAi platform, with Amvuttra’s launch delivering robust U.S. growth and CNS proof-of-concept data opening new addressable markets.

• TTR Franchise Execution: Sustained new patient adds, high compliance, and prescriber expansion support continued above-market growth.
• Pipeline Inflection: CNS RNAi data and hypertension program progress point to a broader, more scalable opportunity set beyond rare disease.
• Future Watchpoints: Monitor regulatory feedback on CNS programs, competitive TTR entries, and key late-stage data readouts for further upside or risk signals.

Conclusion

Alnylam exits Q1 with strong commercial momentum, validated platform expansion, and a robust cash position. The next phase of execution will hinge on translating pipeline milestones into sustainable, differentiated growth across both rare and prevalent diseases.

Industry Read-Through

Alnylam’s successful Amvuttra launch and CNS RNAi milestone signal a new era for RNA-based therapeutics, demonstrating that gene silencing can be both commercially viable and therapeutically versatile. For the broader biotech sector, this quarter underscores the importance of platform innovation, payer access strategies, and the ability to scale from rare to more common diseases. Competitors in the TTR and CNS space will need to match both clinical efficacy and operational execution to sustain relevance. The regulatory scrutiny around CNS delivery and durability will shape the pace of innovation for all RNAi and gene therapy players.

ALNY Healthcare Biotechnology RNAi Rare Disease TTR Franchise CNS Pipeline